NCT02141347 - Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 22, 2014

Primary Completion Date

January 27, 2017

Study Completion Date

January 27, 2017

Conditions

Part A and B: Advanced Solid MalignanciesPart C: Malignant Mesothelioma

Interventions

DRUG

Tremelimumab

Tremelimumab administered intravenously

DRUG

MEDI4736

MEDI4736 administered intravenously.

Trial Locations (11)

Research Site, Bunkyō City

Research Site, Chūōku

Research Site, Hiroshima

Research Site, Nagoya

Research Site, Nishinomiya-shi

Research Site, Okayama

Research Site, Osaka

Research Site, Sapporo

Research Site, Sunto-gun

Research Site, Ube-shi

Research Site, Yokohama